• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Community Acquired Bacterial Pneumonia - Pipeline Review, H2 2012 Product Image

Community Acquired Bacterial Pneumonia - Pipeline Review, H2 2012

  • Published: December 2012
  • 33 pages
  • Global Markets Direct

Community Acquired Bacterial Pneumonia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Community Acquired Bacterial Pneumonia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Community Acquired Bacterial Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Community Acquired Bacterial Pneumonia. Community Acquired Bacterial Pneumonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Community Acquired Bacterial READ MORE >

2
List of Tables 3
List of Figures 3
Introduction 4
REPORT COVERAGE 4
Community Acquired Bacterial Pneumonia Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Community Acquired Bacterial Pneumonia 6
Community Acquired Bacterial Pneumonia Therapeutics under Development by Companies 8
Community Acquired Bacterial Pneumonia Therapeutics under Investigation by Universities/Institutes 9
Late Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Community Acquired Bacterial Pneumonia Therapeutics – Products under Development by Companies 12
Community Acquired Bacterial Pneumonia Therapeutics – Products under Investigation by Universities/Institutes 13
Companies Involved in Community Acquired Bacterial Pneumonia Therapeutics Development 14
Regeneron Pharmaceuticals, Inc. 14
Community Acquired Bacterial Pneumonia – Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Drug Profiles 20
Eylea - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
bevacizumab - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Community Acquired Bacterial Pneumonia Therapeutics – Drug Profile Updates 24
Community Acquired Bacterial Pneumonia – Product Development Milestones 29
Featured News & Press Releases 29
Jul 19, 2012: CHMP Adopted Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Ozurdex 29
Jun 11, 2012: Scottish Medicines Consortium Accepts OZURDEX For Use Within NHS Scotland 29
Apr 27, 2011: Regeneron And Bayer Report Positive Results For VEGF Trap-Eye In Second Phase III Study In Central Retinal Vein Occlusion 30
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Number of Products Under Development for Community Acquired Bacterial Pneumonia, H2 2012 6
Products under Development for Community Acquired Bacterial Pneumonia – Comparative Analysis, H2 2012 7
Number of Products under Development by Companies, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 13
Regeneron Pharmaceuticals, Inc., H2 2012 14
Assessment by Monotherapy Products, H2 2012 15
Assessment by Stage and Route of Administration, H2 2012 17
Assessment by Stage and Molecule Type, H2 2012 19
Community Acquired Bacterial Pneumonia Therapeutics – Drug Profile Updates 24

List of Figures
Number of Products under Development for Community Acquired Bacterial Pneumonia, H2 2012 6
Products under Development for Community Acquired Bacterial Pneumonia – Comparative Analysis, H2 2012 7
Products under Development by Companies, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Late Stage Products, H2 2012 10
Early Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 15
Assessment by Route of Administration, H2 2012 16
Assessment by Stage and Route of Administration, H2 2012 17
Assessment by Molecule Type, H2 2012 18
Assessment by Stage and Molecule Type, H2 2012 19

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos